BRPI0520902A2 - MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT BINDS TO PSCA PROTEINS FOR CANCER DIAGNOSIS, METHOD FOR PRODUCING THE SAME, HIB'RIDOMA, POLYNUCLEOTIDE, VECTOR, CELL, COMPOSITION, ASSAY TO DETECT THE PRESENCE OF A PSCA PROTEIN AND METHOD FOR DETECTING A PSCA PROTEIN - Google Patents

MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT BINDS TO PSCA PROTEINS FOR CANCER DIAGNOSIS, METHOD FOR PRODUCING THE SAME, HIB'RIDOMA, POLYNUCLEOTIDE, VECTOR, CELL, COMPOSITION, ASSAY TO DETECT THE PRESENCE OF A PSCA PROTEIN AND METHOD FOR DETECTING A PSCA PROTEIN

Info

Publication number
BRPI0520902A2
BRPI0520902A2 BRPI0520902A BRPI0520902A2 BR PI0520902 A2 BRPI0520902 A2 BR PI0520902A2 BR PI0520902 A BRPI0520902 A BR PI0520902A BR PI0520902 A2 BRPI0520902 A2 BR PI0520902A2
Authority
BR
Brazil
Prior art keywords
psca
psca protein
ridoma
hib
polynucleotide
Prior art date
Application number
Other languages
Portuguese (pt)
Inventor
Jean Gudas
Aya Jakobovits
Xiao-Chi Jia
Robert Kendall Morrison
Karen Jane Meyrick Morrison
Hui Shao
Pia M Challita-Eid
Arthur B Raitano
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/017231 external-priority patent/WO2005014780A2/en
Application filed by Agensys Inc filed Critical Agensys Inc
Priority claimed from PCT/US2005/017412 external-priority patent/WO2005118864A2/en
Publication of BRPI0520902A2 publication Critical patent/BRPI0520902A2/en
Publication of BRPI0520902B1 publication Critical patent/BRPI0520902B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
BRPI0520902-1A 2004-05-28 2005-05-17 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT BINDS TO PSCA PROTEINS FOR THE DIAGNOSIS OF CANCER, METHOD FOR PRODUCTION THEREOF, HYBRIDOMA, POLYNUCLEOTIDE, VECTOR, COMPOSITION, ASSAY TO DETECT THE PRESENCE OF A PSCA PROTEIN AND METHOD OF DETECTION OF ONE PSCA PROTEIN BRPI0520902B1 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
PCT/US2004/017231 WO2005014780A2 (en) 2003-05-30 2004-05-28 Prostate stem cell antigen (psca) variants and subsequences thereof
US10/857,484 US7622564B2 (en) 2003-05-30 2004-05-28 Prostate stem cell antigen (PSCA) variants and subsequences thereof
US61638104P 2004-10-05 2004-10-05
US60/616,381 2004-10-05
US61788104P 2004-10-12 2004-10-12
US60/617,881 2004-10-12
US62131004P 2004-10-21 2004-10-21
US60/621,310 2004-10-21
US63307704P 2004-12-02 2004-12-02
US60/633,077 2004-12-02
US67200005P 2005-04-14 2005-04-14
US60/672,000 2005-04-14
PCT/US2005/017412 WO2005118864A2 (en) 2004-05-28 2005-05-17 Antibodies and related molecules that bind to psca proteins
BRPI0511624-4A BRPI0511624B1 (en) 2004-05-28 2005-05-17 MONOCLONAL ANTIBODY THAT BINDS TO PSCA PROTEIN, USE OF IT, HYBRIDOMA, VECTOR, PHARMACEUTICAL COMPOSITION, AS WELL AS ASSAY AND METHOD FOR DETECTION OF THE PRESENCE OF A PSCA PROTEIN IN A BIOLOGICAL SAMPLE

Publications (2)

Publication Number Publication Date
BRPI0520902A2 true BRPI0520902A2 (en) 2011-10-25
BRPI0520902B1 BRPI0520902B1 (en) 2021-11-30

Family

ID=44210117

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0520902-1A BRPI0520902B1 (en) 2004-05-28 2005-05-17 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT BINDS TO PSCA PROTEINS FOR THE DIAGNOSIS OF CANCER, METHOD FOR PRODUCTION THEREOF, HYBRIDOMA, POLYNUCLEOTIDE, VECTOR, COMPOSITION, ASSAY TO DETECT THE PRESENCE OF A PSCA PROTEIN AND METHOD OF DETECTION OF ONE PSCA PROTEIN
BR122018073034-0A BR122018073034B1 (en) 2004-05-28 2005-05-17 ANTIBODIES AND RELATED MOLECULES THAT BIND TO PSCA PROTEINS
BRPI0511624-4A BRPI0511624B1 (en) 2004-05-28 2005-05-17 MONOCLONAL ANTIBODY THAT BINDS TO PSCA PROTEIN, USE OF IT, HYBRIDOMA, VECTOR, PHARMACEUTICAL COMPOSITION, AS WELL AS ASSAY AND METHOD FOR DETECTION OF THE PRESENCE OF A PSCA PROTEIN IN A BIOLOGICAL SAMPLE

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR122018073034-0A BR122018073034B1 (en) 2004-05-28 2005-05-17 ANTIBODIES AND RELATED MOLECULES THAT BIND TO PSCA PROTEINS
BRPI0511624-4A BRPI0511624B1 (en) 2004-05-28 2005-05-17 MONOCLONAL ANTIBODY THAT BINDS TO PSCA PROTEIN, USE OF IT, HYBRIDOMA, VECTOR, PHARMACEUTICAL COMPOSITION, AS WELL AS ASSAY AND METHOD FOR DETECTION OF THE PRESENCE OF A PSCA PROTEIN IN A BIOLOGICAL SAMPLE

Country Status (6)

Country Link
KR (2) KR101282396B1 (en)
CN (1) CN102344493B (en)
BR (3) BRPI0520902B1 (en)
IL (1) IL214210A (en)
NO (1) NO341404B1 (en)
SI (1) SI1753871T1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2140269T3 (en) 2007-03-27 2013-12-16 Immunovia Ab PROTEIN SIGNATURE / MARKERS TO DETECT ADENOCARCINOM
SG10201912773TA (en) * 2012-08-23 2020-02-27 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
KR20230156146A (en) 2012-12-13 2023-11-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Dna antibody constructs and method of using same
WO2015089492A2 (en) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
BR112017011556A2 (en) 2014-12-01 2018-03-06 The Trustees Of The University Of Pennsylvania methods for generating a synthetic antibody, preventing or treating a disease, treating a subject of pathogen infection and a subject with cancer, product, nucleic acid molecule, and composition.
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN119930826A (en) * 2023-11-02 2025-05-06 重庆精准生物产业技术研究院有限公司 Fully humanized single-chain antibody against PSCA and its application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343085B1 (en) * 1997-03-10 2014-12-10 The Regents of The University of California Antibody against prostate stem cell antigen (PSCA)
US6258939B1 (en) * 1997-03-10 2001-07-10 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
BR0015224A (en) * 1999-10-29 2002-07-09 Genentech Inc Isolated prostatic stem cell (psca) anti-antigen, monoclonal anti-psca antibody, isolated nucleic acid, expression vector, cell, host cell, antibody production method, in vitro method composition to kill a cancer cell that expresses psca , use of an anti-psca monoclonal antibody and industrialized article

Also Published As

Publication number Publication date
BR122018073034B8 (en) 2022-10-11
KR20110056564A (en) 2011-05-30
KR20070047251A (en) 2007-05-04
IL214210A (en) 2013-01-31
KR101215611B1 (en) 2012-12-28
KR101282396B1 (en) 2013-07-04
BRPI0520902B1 (en) 2021-11-30
NO341404B1 (en) 2017-10-30
BRPI0511624B1 (en) 2022-02-08
SI1753871T1 (en) 2016-01-29
IL214210A0 (en) 2011-08-31
CN102344493A (en) 2012-02-08
NO20110647L (en) 2006-12-19
BR122018073034B1 (en) 2021-10-13
BRPI0511624A (en) 2008-01-02
CN102344493B (en) 2014-09-03

Similar Documents

Publication Publication Date Title
BRPI0308585B8 (en) isolated antibody or antigen-binding fragment thereof that binds to alfavbeta6, composition, in vitro detection method of alfavbeta6, and DNA construction
BRPI0818437A2 (en) Antibody or functional fragment of the antibody, pharmaceutical composition, use of at least one of the antibodies or functional fragments of the antibodies, and hybridoma
BR112012007365A2 (en) il-1 binding proteins
BRPI0816117B8 (en) isolated monoclonal antibody or fragment thereof, pharmaceutical composition, kit for treating cholesterol-related disorders, and use of an antigen-binding protein or a monoclonal antibody or fragment thereof
EA201100527A1 (en) BIOLOGICAL PRODUCTS
BR112012009846A2 (en) Assays for detection of specific antibodies for therapeutic anti-IgE antibodies and their use in anaphylaxis
WO2007061793A3 (en) Modified cardiolipin and uses therefor
WO2006086208A3 (en) 5-fluoro-uracil immunoassay
ATE464374T1 (en) ASSAY FOR THE RAPID DETECTION OF HUMAN ACTIVATED PROTEIN C AND HIGHLY SPECIFIC MONOCLONAL ANTIBODIES AGAINST IT
HRP20161398T1 (en) Anti-idiotype antibody against an antibody against the amyloid beta peptide
EP3665187A4 (en) ASSAY METHODS FOR ENHANCED ANALYTE DETECTION
EP1708745A4 (en) ANTIBODIES FOR ONCOGEN STRAINS OF HPV AND METHODS OF USE
ATE412179T1 (en) DETECTION OF MEDICINAL MEDICINAL OF THE METHAMPHETAMINE GROUP
WO2008101177A3 (en) Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
FI961004A0 (en) determination Package
ATE477278T1 (en) MONOCLONAL ANTIBODY AGAINST HUMAN FRIZZLED-4 RECEPTOR
EP1643894A4 (en) METHODS, KITS AND ANTIBODIES FOR DETECTION OF PARATHORMONE
WO2006102200A3 (en) Docetaxel immunoassay
WO2008054724A3 (en) Monoclonal antibodies against osteopontin
WO2003046140A3 (en) Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
IL214210A0 (en) Antibodies that bind psca proteins for diagnosis of cancer
ATE405837T1 (en) SOLID PHASE IMMUNOCHROMATOGRAPHIC TESTING METHODS
EP1891108A4 (en) REAGENTS AND DIAGNOSTIC ASSAYS FOR DETECTION OF PSP94 PROTEIN
CA2589054A1 (en) Detection of a therapeutic antibody in an experimental animal
WO2004084841A3 (en) Novel anti-feline albumin antibodies and methods of detecting early renal disease

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2204 DE 02/04/2013.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/05/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.